Literature DB >> 282

[Combined use of bucolome and pyrazolone derivatives (II). Complex formation due to interaction between bucolome and pyrazolones].

M Nozaki.   

Abstract

We have already reported that bucolome (BCP), a non-steroidal anti-inflammatory agent, potentiates significantly the analgesic and antipyretic effects of pyrazolones which are substituted by alkylamino group at 4-position of the pyrazolone ring. Physical and quantum chemistry were applied to the mechanism of this synergistic action. The solubility of BCP was markedly increased in proportion to elevation of aminopyrine (AM) concentration, but not by a combination with isopropylantipyrine (IP). The binding of BCP to bovine serum albumin was slightly inhibited by AM, but not by IP. The mixture of AM and BCP in aqueous media generated optical absorption in the ultraviolet differential spectrum, due to the charge transfer interaction. The results of the infrared or NMR spectrum demonstrated the formation of a hydrogen binding in non-aqueous media between BCP and AM. From the calculation of the charge on an atom, the energy of the highest occupied molecular orbital and the frontier electron density, BCP is considered to be a good electron acceptor. The beta-units of Mho of pyrazolones were found to correlate with the potentiation coefficient of analgesic activity in combination drugs. These results suggest that the complex formation between BCP and pyrazolones is an important factor for the synergism of action and is due to the charge transfer interaction and the hydrogen binding of both molecules.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 282

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


  13 in total

Review 1.  Giving or withholding fluid and nutrients: ethical and legal aspects.

Authors:  J E Lennard-Jones
Journal:  J R Coll Physicians Lond       Date:  1999 Jan-Feb

2.  Decisions Relating to Cardiopulmonary Resuscitation: a joint statement from the British Medical Association, the Resuscitation Council (UK) and the Royal College of Nursing.

Authors: 
Journal:  J Med Ethics       Date:  2001-10       Impact factor: 2.903

Review 3.  The use of opioids and sedatives at the end of life.

Authors:  Nigel Sykes; Andrew Thorns
Journal:  Lancet Oncol       Date:  2003-05       Impact factor: 41.316

4.  Lethal opioids or dangerous prescribers?

Authors:  Rob George; Claud Regnard
Journal:  Palliat Med       Date:  2007-03       Impact factor: 4.762

5.  Evaluation and ethical review of a tool to explore patient preferences for information and involvement in decision making.

Authors:  F E M Murtagh; A Thorns
Journal:  J Med Ethics       Date:  2006-06       Impact factor: 2.903

Review 6.  In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival.

Authors:  Claudio Sandroni; Jerry Nolan; Fabio Cavallaro; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2006-09-22       Impact factor: 17.440

7.  Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database.

Authors:  J P Nolan; S R Laver; C A Welch; D A Harrison; V Gupta; K Rowan
Journal:  Anaesthesia       Date:  2007-12       Impact factor: 6.955

Review 8.  Medically assisted hydration for palliative care patients.

Authors:  P Good; J Cavenagh; M Mather; P Ravenscroft
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 9.  Truth-telling in discussing prognosis in advanced life-limiting illnesses: a systematic review.

Authors:  Karen Hancock; Josephine M Clayton; Sharon M Parker; Sharon Wal der; Phyllis N Butow; Sue Carrick; David Currow; Davina Ghersi; Paul Glare; Rebecca Hagerty; Martin H N Tattersall
Journal:  Palliat Med       Date:  2007-09       Impact factor: 4.762

10.  Respiratory function during parenteral opioid titration for cancer pain.

Authors:  Bassam Estfan; Fade Mahmoud; Philip Shaheen; Mellar P Davis; Wael Lasheen; Nilo Rivera; Susan B Legrand; Ruth L Lagman; Declan Walsh; Lisa Rybicki
Journal:  Palliat Med       Date:  2007-03       Impact factor: 4.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.